Stryker Q3 Preview: Analysts Trim Targets, Stock Rebounds

Stryker Corporation enters its Q3 earnings report today with a stock that has recovered sharply even as the analyst community has spent two months cutting price targets.

The debate around Stryker is unusually well-defined. Bulls point to the company's position as a core MedTech holding: market-leading orthopedic robotics, a broad surgical equipment portfolio, and management guidance for 8.0 to 9.5% organic sales growth in FY26 with 150 basis points of EBIT margin expansion through 2028. Bears counter that the second half has proven harder than expected. Supply and manufacturing disruptions tied to the March cyber event are still weighing on Peripheral Vascular, Joint Replacement demand has softened in the U.S. summer period, and European volumes remain weak. The practical consequence is that organic revenue growth for 2026 looks likely to land at the low end of guidance, around 8.0 to 8.3%, with adjusted EPS estimates clustering near $14.92 to $14.96, close to the bottom of the $14.95 to $15.10 range management provided. The analyst consensus sits at hold, with seven hold ratings recorded as of October 27. Multiple firms trimmed targets since September: Wells Fargo cut from $418 to $348, BTIG moved from $358 to $316 in October, and Truist dropped to $310. Barclays initiated at Overweight with a $375 target on October 7, offering a contrarian note of optimism, but the overall direction of travel on the Street has been downward. The factor score for analyst recommendation divergence ranks in the 94th percentile, a signal that the spread between the most optimistic and most cautious views on the stock is unusually wide.

Short interest does not tell an especially aggressive story. Bears reduced positions sharply through early October, with shares short falling from roughly 7.9 million in late September to around 5.4 million by October 9. There has been a partial rebuild since, with short interest edging back to 6.0 million shares, or 1.6% of the free float, as of October 28, including a 7% rise over the past week. Borrow costs are low at 0.45%, down 21% over the week. Availability in the lending pool remains exceptionally loose at 4,138% of short interest, meaning shorts face no structural constraint. Positioning looks sceptical rather than aggressively bearish.

The price action complicates the picture for bears. Stryker gained 13% over the past month to close at $311.75, a 2.5% move on Wednesday alone. That stands against a median one-week move of -0.3% for its closest peers, including ZBH, MMSI and MDT. The July Q2 print was a reference point: the stock fell 7.5% the day after results and a further 4.2% over the following five days, the only recent quarter with a recorded price reaction. The Q3 print is therefore less about whether Stryker is growing and more about whether management can demonstrate the cyber disruption is behind it and that the low end of guidance holds at a valuation that has re-rated 2.1 points higher on a trailing P/E basis over the past month.